These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 20828221

  • 1. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H.
    Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
    [Abstract] [Full Text] [Related]

  • 2. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T.
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [Abstract] [Full Text] [Related]

  • 3. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators.
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, Wakatsuki T, Orino S, Kawano K, Sata M.
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [Abstract] [Full Text] [Related]

  • 6. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H, Ando K, Ueshima K, Babazono T, Kario K, Tanaka S, Nakao K, Fujita T, SAKURA Trial Investigators.
    Clin Exp Hypertens; 2011 Nov; 33(7):455-62. PubMed ID: 21649534
    [Abstract] [Full Text] [Related]

  • 7. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [Abstract] [Full Text] [Related]

  • 8. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S, Yano Y, Maki K, Iwasaka T.
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [Abstract] [Full Text] [Related]

  • 9. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 10. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [Abstract] [Full Text] [Related]

  • 11. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K.
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [Abstract] [Full Text] [Related]

  • 12. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 13. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ.
    Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
    [Abstract] [Full Text] [Related]

  • 14. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
    Kojima S, Shida M, Yokoyama H.
    Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
    [Abstract] [Full Text] [Related]

  • 15. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials.
    Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW.
    Blood Press Monit; 2010 Aug; 15(4):195-204. PubMed ID: 20512032
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.
    Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K.
    Hypertens Res; 2005 Dec; 28(12):1003-8. PubMed ID: 16671340
    [Abstract] [Full Text] [Related]

  • 17. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 18. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
    Seino H, Miyaguchi S, Yamazaki T, Ota S, Yabe R, Suzuki S.
    Arzneimittelforschung; 2007 Apr 25; 57(8):526-31. PubMed ID: 17915639
    [Abstract] [Full Text] [Related]

  • 19. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun 25; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 20. [Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension].
    Shal'nova SA, Martsevich SIu, Deev AD, Kutishenko NP, Kukushkin SK, Manoshkina EM, Alimova EV, Semenova IuE, Lebedev AV, Koniakhina IP, Zagrebel'nyĭ AV.
    Ter Arkh; 2000 Jun 25; 72(10):86-9. PubMed ID: 11220888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.